Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;70(4):e250-e261.
doi: 10.1016/j.jpainsymman.2025.07.006. Epub 2025 Jul 14.

Buprenorphine-Naloxone for Chronic Cancer-Related Pain in a Palliative Care Clinic

Yoko Tarumi  1 , Vickie Baracos  2 , Sonya Lowe  3 , Ayoola Ademola  4 , Allison Chabassol  3 , Tracy Wildeman  5 , Megan Sellick  6 , Jennifer Dutka  5 , Vincent Ha  5 , Sharon M Watanabe  3
Affiliations

Buprenorphine-Naloxone for Chronic Cancer-Related Pain in a Palliative Care Clinic

Yoko Tarumi et al. J Pain Symptom Manage. 2025 Oct.

Abstract

Context: Long-term opioid therapy (LTOT) for chronic cancer-related pain can lead to negative consequences.

Objectives: To describe the use of buprenorphine, a pharmacologically unique opioid, combined with naloxone (Bup-Nal) for chronic cancer-related pain requiring LTOT.

Methods: Retrospective descriptive study conducted in a tertiary cancer center-based palliative care clinic. Routinely collected data were analyzed.

Results: A total of 47 persons with advanced cancer underwent switches to Bup-Nal from previous opioids. Mean/median ages were 56.2/56.5 years old. All were on disease-modifying treatment. Mean/median duration in months of previous opioid use prior to switch were 18.3 (standard deviation [SD]: 15.0)/14.0 (interquartile range [IQR]: 6.0-24.0). Mean/median oral morphine equivalent daily dose (MEDD) in mg prior to switch were 122.4 (SD: 98.8)/100.0 (IQR: 54.0-165.0). Mean/median total daily dose of buprenorphine in mg at stable pain control were 4.6 (SD: 4.9)/2.0 (IQR: 1.0-6.5). Mean/median dose conversion ratios for oral MEDD:sublingual buprenorphine were 39.4 (SD: 19.4)/35.8 (IQR: 26.6-50.0). Mean/median durations of Bup-Nal use in months were 6.7 (SD: 7.9)/4.0 (IQR: 2.0-8.0). Analysis of variance revealed that mean Edmonton Symptom Assessment System-Revised pain score diminished over time (chi-square: 36.0, P-value ≤0.001). Bup-Nal use >three months had greater pain score reduction over the 12-week observation period.

Conclusion: This retrospective descriptive study demonstrates that persons with advanced cancer and chronic cancer-related pain requiring LTOT could be successfully switched from other opioids to Bup-Nal, with a statistically significant decrease in pain over time, which was more pronounced in those on Bup-Nal for >three months. Prospective studies are warranted.

Keywords: Ambulatory palliative care; Buprenorphine-naloxone; Chronic cancer-related pain; Long-term opioid therapy; Opioid switch; Sublingual buprenorphine.

PubMed Disclaimer

LinkOut - more resources